TADALAFIL (tadalafil) by Cipla is phosphodiesterase 5 inhibitors [moa]. Approved for phosphodiesterase 5 inhibitor [epc]. First approved in 2019.
Drug data last refreshed 21h ago
Phosphodiesterase 5 Inhibitors
Phosphodiesterase 5 Inhibitor
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Actual Use Trial of Tadalafil 5 mg
Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH
Clinical Investigation Using MED3000 Gel or Tadalafil Tablets in the Treatment of Erectile Dysfunction
A Study of Macitentan/Tadalafil Combination Administered a Fixed-dose Combination Formulation Compared to the Reference Free Combination of Macitentan and Tadalafil
A Study of Macitentan and Tadalafil as a Fixed Dose Combination and the Free Combination in Healthy Adult Participants
Worked on TADALAFIL at Cipla? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.